NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price & News $127.10 -0.49 (-0.38%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$126.60▼$128.7050-Day Range$125.90▼$147.1652-Week Range$125.35▼$163.31Volume423,869 shsAverage Volume582,269 shsMarket Capitalization$8.13 billionP/E RatioN/ADividend YieldN/APrice Target$200.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jazz Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside57.9% Upside$200.75 Price TargetShort InterestBearish4.64% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.44Based on 12 Articles This WeekInsider TradingSelling Shares$1.15 M Sold Last QuarterProj. Earnings Growth13.74%From $14.70 to $16.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.62 out of 5 starsMedical Sector78th out of 988 stocksPharmaceutical Preparations Industry29th out of 482 stocks 3.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $200.75, Jazz Pharmaceuticals has a forecasted upside of 57.9% from its current price of $127.10.Amount of Analyst CoverageJazz Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.64% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 19.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 2.5 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest10 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,147,670.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.79% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 13.74% in the coming year, from $14.70 to $16.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -50.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -50.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.72. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jazz Pharmaceuticals (NASDAQ:JAZZ) StockJazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.Read More Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesJune 9, 2023 | finance.yahoo.comWhy Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?June 9, 2023 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)June 10, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. June 7, 2023 | americanbankingnews.comNeena M. Patil Sells 1,600 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockJune 5, 2023 | markets.businessinsider.comGoldman Sachs Remains a Buy on Jazz Pharmaceuticals (JAZZ)June 1, 2023 | msn.comCramer's Lightning Round: Novavax is a no-goMay 31, 2023 | finance.yahoo.comJazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023May 30, 2023 | finanznachrichten.deJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare ConferenceJune 10, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 30, 2023 | finance.yahoo.comJazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare ConferenceMay 30, 2023 | americanbankingnews.comBrokers Issue Forecasts for Jazz Pharmaceuticals plc's Q2 2023 Earnings (NASDAQ:JAZZ)May 27, 2023 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 52-Week Low at $125.35May 26, 2023 | americanbankingnews.comQ1 2025 Earnings Forecast for Jazz Pharmaceuticals plc Issued By Zacks Research (NASDAQ:JAZZ)May 26, 2023 | benzinga.comJazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS SpasticityMay 25, 2023 | finance.yahoo.comJazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023May 18, 2023 | finance.yahoo.comZymeworks Announces Departure of Neil Klompas, President and Chief Operating OfficerMay 17, 2023 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Large Increase in Short InterestMay 17, 2023 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Up 7.4% in AprilMay 17, 2023 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $200.75 Consensus Price Target from AnalystsMay 16, 2023 | seekingalpha.comJazz Pharmaceuticals plc 2023 Q1 - Results - Earnings Call PresentationMay 16, 2023 | msn.comHC Wainwright & Co. Reiterates Jazz Pharmaceuticals (JAZZ) Buy RecommendationMay 16, 2023 | americanbankingnews.comKineta (NASDAQ:KA) vs. Jazz Pharmaceuticals (NASDAQ:JAZZ) Head to Head ContrastMay 15, 2023 | msn.comNeedham Reiterates Jazz Pharmaceuticals (JAZZ) Buy RecommendationMay 15, 2023 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2023 Earnings GuidanceMay 13, 2023 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $212.00 at Needham & Company LLCMay 12, 2023 | msn.comNeedham Maintains Jazz Pharmaceuticals (JAZZ) Buy RecommendationMay 12, 2023 | msn.comRBC Capital Maintains Jazz Pharmaceuticals (JAZZ) Outperform RecommendationSee More Headlines JAZZ Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Company Calendar Last Earnings11/09/2021Today6/09/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Forecast$200.75 High Stock Price Forecast$212.00 Low Stock Price Forecast$187.00 Forecasted Upside/Downside+57.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.54) Trailing P/E RatioN/A Forward P/E Ratio8.65 P/E Growth0.73Net Income$-224,060,000.00 Net Margins-4.18% Pretax Margin-8.67% Return on Equity24.72% Return on Assets7.03% Debt Debt-to-Equity Ratio1.71 Current Ratio3.06 Quick Ratio2.32 Sales & Book Value Annual Sales$3.66 billion Price / Sales2.22 Cash Flow$21.84 per share Price / Cash Flow5.82 Book Value$49.01 per share Price / Book2.59Miscellaneous Outstanding Shares64,000,000Free Float61,184,000Market Cap$8.13 billion OptionableOptionable Beta0.74 Social Links Key ExecutivesBruce C. CozaddChairman & Chief Executive OfficerDaniel N. SwisherPresidentRenée D. GaláChief Financial Officer & Executive Vice PresidentRobert IannoneExecutive Vice President-Research & DevelopmentFinbar LarkinSenior Vice President-Technical OperationsKey CompetitorsPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTHorizon Therapeutics PublicNASDAQ:HZNPTeva Pharmaceutical IndustriesNYSE:TEVAKaruna TherapeuticsNASDAQ:KRTXView All CompetitorsInsiders & InstitutionsPatricia CarrSold 126 sharesTotal: $16,117.92 ($127.92/share)Macquarie Group Ltd.Bought 8,237 shares on 6/1/2023Ownership: 0.060%Neena M PatilSold 1,600 sharesTotal: $204,768.00 ($127.98/share)Ontario Teachers Pension Plan BoardBought 4,992 shares on 6/1/2023Ownership: 0.033%ProShare Advisors LLCSold 1,929 shares on 5/26/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions JAZZ Stock - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price forecast for 2023? 8 equities research analysts have issued 1 year price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $212.00. On average, they anticipate the company's stock price to reach $200.75 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2023? Jazz Pharmaceuticals' stock was trading at $159.31 on January 1st, 2023. Since then, JAZZ shares have decreased by 20.2% and is now trading at $127.10. View the best growth stocks for 2023 here. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, topping the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 4.18% and a positive trailing twelve-month return on equity of 24.72%. During the same quarter in the previous year, the business earned $3.86 earnings per share. What ETFs hold Jazz Pharmaceuticals' stock? ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), Amplify Seymour Cannabis ETF (CNBS), AdvisorShares Pure Cannabis ETF (YOLO), SPDR S&P Pharmaceuticals ETF (XPH), Subversive Mental Health ETF (SANE), iShares U.S. Pharmaceuticals ETF (IHE), Invesco Dynamic Pharmaceuticals ETF (PJP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of $16.90-$17.85 for the period, compared to the consensus estimate of $17.44. The company issued revenue guidance of $3.67 billion-$3.88 billion, compared to the consensus revenue estimate of $3.78 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.40%), State Street Corp (3.64%), LSV Asset Management (3.66%), JPMorgan Chase & Co. (3.32%), Wellington Management Group LLP (2.90%) and Polaris Capital Management LLC (2.07%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone and Samantha Pearce. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $127.10. How much money does Jazz Pharmaceuticals make? Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $8.13 billion and generates $3.66 billion in revenue each year. The specialty pharmaceutical company earns $-224,060,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. How many employees does Jazz Pharmaceuticals have? The company employs 2,800 workers across the globe. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850. This page (NASDAQ:JAZZ) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.